Highlights in chronic lymphocytic leukemia

Size: px
Start display at page:

Download "Highlights in chronic lymphocytic leukemia"

Transcription

1 Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic leukemia (CLL) will be presented in the following summary. The recently published updated BHS guidelines for the treatment of CLL, anno 2016, incorporated obinutuzumab, ibrutinib and idelalisib. Results of multiple plase 3 trials were presented at ASH 2015 and will probably challenge the proposed guidelines in the near future. 1 (Belg J Hematol 2016;7(1):3-8) Adding idelalisib to bendamustine/ rituximab delays progression and prolongs survival in relapsed/ refractory CLL Idelalisib is a first-in-class targeted PI3k-delta inhibitor approved, in combination with rituximab, for the treatment of patients with relapsed/refractory (R/R) CLL and as first-line treatment for patients with a 17p deletion or a TP53 mutation that are unsuitable for chemo-immunotherapy (CIT). The results of a randomized, placebo-controlled phase 3 study evaluating the efficacy of idelalisib added to bendamustine-rituximab (BR), a common CIT regimen for R/R CLL, were communicated as a late breaking abstract. The independent review committee (IRC) recommended unblinding the study based on overwhelming efficacy. In total, 416 patients were randomized to BR for 6 cycles and idelalisib 150mg BID or placebo continuously. Treatment with idelalisib or placebo was administered until disease progression (PD), death, intolerable toxicity, or withdrawal of consent. Crossover was not permitted at the time of PD. The interim analysis demonstrated that progression free survival (PFS) (23 vs. 11 months (HR: 0.33, p<0.0001)) (Figure 1), the primary endpoint, and overall survival (OS) (not reached for either arm (HR: 0.55, p=0.008)), a secondary endpoint, were superior in the investigational vs. control arm. The most common grades 3 AEs with idelalisib + BR were neutropenia (60%) and febrile neutropenia (20%) and were neutropenia (46%), anemia and thrombocytopenia (both 12%) with BR + placebo. 2 Treatment with idelalisib added to BR was superior to BR in terms of PFS, OS and overall response rate (ORR) in R/R CLL with a 67% and 45% reduction in the risk of progression and death, without new safety signals seen with the combination. Idelalisib added to BR could be a new treatment option for patients with R/R CLL. 2 Ibrutinib as initial therapy for patients with CLL Ibrutinib is a first-in-class, oral, covalent inhibitor of Bruton s tyrosine kinase approved for patiens with R/R CLL and 17p deleted CLL patients (including first-line). Ibrutinib also showed high activity in treatment-naïve patients age 65 years. A randomized, open-label phase 3 trial to evaluate efficacy and safety of single-agent ibrutinib (420mg daily until progression) vs. chlorambucil (clb) (0.5mg/kg (up to 0.8mg/kg) on days 1 and 15 of a 28-day cycle for up to 12 cycles) in treatment-naïve patients (N=269) without 17p deletion, aged 65 years with CLL/SLL has been conducted. Patients with IRC-confirmed progres- 1 Department of Hematology, UZ Leuven. Please send all correspondence to: Ann Janssens, MD, PhD, Department of Hematology, UZ Leuven, Herestraat 49, 3000 Leuven, Tel: +32 (0) , ann.janssens@uzleuven.be Conflict of interest: The author has nothing to disclose and indicated no potential conflict of interest. 3

2 1 Special Edition sion could be treated with ibrutinib in an extension study. At a median follow-up of 18.4 months, ibrutinib significantly prolonged PFS, the primary endpoint, vs. clb (median not reached vs months; HR: 0.16, p<0.0001). This was consistent within subgroups including age 70 years, 11q deletion, and unmutated IGV H. Ibrutinib also significantly prolonged OS, a secondary endpoint vs. clb (median not reached for either arm; HR: 0.16, p=0.0010). The most frequent AEs with ibrutinib included diarrhea, fatigue, cough and nausea, while the most frequent AEs with clb were nausea, fatigue, neutropenia, anemia and vomiting. AEs leading to treatment discontinuation were less frequent with ibrutinib (9% vs. 23%). Atrial fibrillation (AF) occurred in 6% with ibrutinib and 1% with clb. Hypertension was noted more frequently on ibrutinib and managed without ibrutinib dose modification or discontinuation. Major hemorrhage occurred in 4% with ibrutinib over a median follow-up of approximately 1.5 years, and in 2% with clb. At the time of study closure, 87% of patients randomized to ibrutinib continue to receive ibrutinib. 3 Treatment with single-agent ibrutinib was superior to clb in terms of PFS, OS, ORR, and hematologic improvement in treatment-naïve older CLL/SLL patients, with an 84% reduction in risk of progression and death, and an acceptable safety profile. 3 Improved quality of response by adding ibrutinib to bendamustine/rituximab in previously treated CLL/SLL patients Recent results from the HELIOS phase 3 study in R/R CLL/SLL (N=578) patients demonstrated that the addition of ibrutinib to BR leads to an 80% and 45% reduction in risk of progression and death as compared to placebo + BR. 4 ORR and rates of complete response (CR) or CR with incomplete marrow recovery (CRi) were significantly improved with ibrutinib + BR (ORR: 82.7% vs. 67.8%; CR/CRi: 10.4% vs. 2.8%). Additional analyses on the quality of response with ibrutinib combined with BR were reported. Minimal residual disease (MRD) was assessed by flow cytometry using an 8-color panel. IRC assessed as complete resolution of lymph nodes (34.6% vs. 15.2%), spleen (56.7% vs. 37.0%), overall radiology (21.1% vs. 9.0%), and bone marrow (19.7% vs. 5.9%) was more frequently achieved in the ibrutinib + BR arm in comparison with placebo + BR. MRD was assessed in 120 patients treated with ibrutinib + BR and 57 patients treated with placebo + BR and was negative in 37 and 14 patients, respectively, which corresponds with an MRD-negative response rate of 12.8% vs. 4.8% for ibrutinib + BR vs. placebo + BR (p=0.0011). The percentage of patients with an MRD level < 1% was higher with ibrutinib + BR vs. placebo + BR (32.2% vs. 11.8%). Moreover, the percentage of patients with an MRD level <0.1% was higher for ibrutinib + BR vs placebo + BR (24.6% vs. 7.6%) suggesting that the depth of response with ibrutinib + BR was superior. Kaplan-Meier plots by MRD level show that a lower MRD level was associated with a longer PFS. However, patients in the ibrutinib + BR arm had a more sustained response at every MRD level compared with patients in the placebo + BR arm. 5 Patients treated with ibrutinib + BR showed a greater depth of response, with more CRs and a higher rate of resolution of lymph nodes, spleen, and bone marrow involvement. Furthermore, the rate and depth of MRD negativity was improved, and appeared to last longer in patients treated with ibrutinib + BR as compared to patients receiving placebo + BR. 5 Impact of high-risk prognostic parameters on the outcome of ibrutinib plus bendamustine/rituximab in relapsed CLL/SLL The presented analysis reported on the efficacy of ibrutinib + BR vs. placebo + BR in patients in the HELIOS trial with relevant high-risk biomarkers. Subgroups of patients with 11q deletion, complex karyotype, unmutated IGV H and elevated ZAP70 levels, had a significantly longer PFS with the addition of ibrutinib to BR as compared with placebo + BR. As expected, each of these adverse prognostic parameters had a negative impact on PFS in the placebo + BR arm. The median PFS was shortest in patients with a complex karyotype (8.5 vs months in patients without complex karyotype) and in patients with unmutated IGV H (11.3 vs months in patients with mutated IGV H ). Interestingly, in the ibrutinib + BR arm, the adverse impact of these risk factors could not be detected (median PFS 4

3 Congress Highlights CLL Probability of PFS (%) Median PFS (mo) HR (95% CI) p-value IDELA + BR BR + Placebo (0.24, 0.45) < Median follow-up time = 12 months No. at risk (events) Time (months) IDELA + BR 207 (0) 154 (25) 74 (51) 27 (61) 6 (63) 1 (643) BR + Placebo 209 (0) 145 (46) 36 (111) 11 (126) 1 (131) 0 (132) HR, hazard ratio; IRC, independent review committee. Figure 1. Adding idelalisib to bendamustine-rituximab significantly improves progression-free survival. 2 not reached irrespective of the presence of risk factors). In patients with an 11q deletion, unmutated IGV H, or elevated ZAP70, there were also statistically significant benefits in OS for those receiving ibrutinib + BR vs. placebo + BR (11q deletion: HR: 0.326, p=0.025; unmutated IGV H : HR: 0.515, p=0.017; elevated ZAP70, HR 0.536, p=0.048). Addition of ibrutinib also increased PFS in patient subgroups with other cytogenetic or clinical prognostic markers (such as del13q or bulky disease) compared with placebo. 6 All subgroups of patients, irrespective of adverse risk factors, such as 11q deletion, complex karyotype, elevated ZAP70, and unmutated IGV H, benefit from the addition of ibrutinib to BR as compared to placebo + BR. The negative impact of these known risk factors is not seen in the ibrutinib + BR arm. These results suggest that ibrutinib + BR is a suitable treatment regimen for all patients with previously treated CLL/SLL, including those with high-risk prognostic markers. 6 Management of adverse events to ibrutinib + BR in patients with previously treated CLL/SLL The safety and management of AEs with ibrutinib + BR vs. placebo + BR in HELIOS were also examined. Rates of infection in the ibrutinib + BR and placebo + BR arms were similar (all-grade, 70.4%; grade 3, 26.8% vs. all-grade, 70.0%; grade 3, 22.6%, respectively). Rates of all-grade anemia were 22.3% with ibrutinib + BR and 28.9% with placebo + BR. Patients also required fewer transfusions with ibrutinib + BR. Similar proportions of patients used growth factors in both arms (54% vs. 52%, respectively). Grade 3/4 neutropenia was reported at similar rates in both arms (53.7% vs. 50.5%, respectively). Rates of thrombocytopenia were slightly higher with ibrutinib + BR (30.7%) than placebo + BR (24.0%), but rates of grade 3/4 events were similar between arms (15.0% each arm). AF was observed more frequently in patients on ibrutinib + BR than placebo + BR (7.3% vs. 2.8%). Importantly, in those with a prior history of AF or abnormal heart rhythm, 7/25 receiving ibrutinib + BR and 2/22 receiving placebo + BR developed AF/atrial flutter on 5

4 1 Special Edition study. The rates of any-grade bleeding were 31.0% and 14.6%, respectively, with the majority being grade 1. Many patients (41.8% ibrutinib + BR, 41.1% placebo + BR) were receiving concomitant anticoagulant/antiplatelet medication. A low rate of treatment-related lymphocytosis was observed in both arms (7.0% ibrutinib + BR, 5.9% placebo + BR). The majority of cases resolved within 2 weeks. 7 The addition of ibrutinib to BR was well tolerated and did not significantly impact the safety profile of BR. In addition, ibrutinib was associated with reduced rates of anemia and transfusional support. Consistent with its known toxicity profile, patients in the ibrutinib + BR arm had higher rates of bleeding (mostly grade 1 or 2) and AF; however, few patients discontinued therapy as a result of these AEs. Taken together, the results from HELIOS establish the significant efficacy of ibrutinib and also the overall positive risk-benefit profile of ibrutinib + BR. 7 The adjusted indirect comparisons suggest superiority of single-agent ibrutinib over BR for PFS and OS in patients with R/R CLL/SLL. This comparison also suggest that the addition of BR to ibrutinib did not improve PFS or OS compared with single-agent ibrutinib. Longer follow-up in the ibrutinib arms of these studies will be required to give an indication of whether CIT adds any benefit to ibrutinib for PFS and OS. Overall, these findings provide support for single-agent ibrutinib as an appropriate choice for all patients with R/R CLL/SLL. 8 Indirect comparison of single-agent ibrutinib vs. BR or ibrutinib + BR in patients with R/R CLL/SLL. In two large phase 3 trials of patients with R/R CLL/SLL, single-agent ibrutinib was superior to ofatumumab and ibrutinib + BR was superior to placebo + BR (HELIOS). In the absence of head-to-head evaluations of singleagent ibrutinib vs. BR or ibrutinib + BR, indirect comparisons can provide insights on the relative efficacy of both treatments. As such, an indirect comparative analysis of data from RESONATE and HELIOS was performed. In the overall CLL/SLL and CLL only population, the PFS (Figure 2) and OS were comparable for single-agent ibrutinib vs. ibrutinib + BR, and were significantly improved for single-agent ibrutinib vs. BR. Singleagent ibrutinib reduced the risk of progression/death by 87% vs. BR and the risk of death by 55% vs. BR. 8 Favorable outcomes in CLL patients with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation There are limited data regarding real world practice patterns of BCRi discontinuation and response to subsequent therapies. Two centers reported an extremely poor prognosis for patients failing ibrutinib. For patients failing idelalisib, no data are available. Ten large American cancer centers collaborated to capture the experience of 178 CLL patients who discontinued ibrutinib (N=143) or idelalisib-based (N=35) regimens focusing on reasons for discontinuation and response to subsequent BCRi therapies. The most common reasons for BCRi discontinuation were toxicity (51% ibrutinib, 52% idelalisib), CLL progression (28% ibrutinib, 31% idelalisib), and Richter transformation (RT) DLBCL (8% ibrutinib, 6% idelalisib). The most common toxicities leading to ibrutinib discontinuation were AF, infection, hematologic toxicity, bleeding and pneumonitis. Pneumonitis, colitis, rash and transaminitis were the idelalisib toxicities leading to discontinuation. At the time of analysis, 74 (41%) patients following BCRi discontinuation received a first salvage regimen (CIT, ibrutinib or idelalisib-based, anti-cd20 monoclonal antibody, BCL2-inhibitor, cellular therapy, experimental BCRi, IMID or other treatment). In evaluable patients, the ORR to non-bcri therapies was 40%. ORR to idelalisib-based therapy following ibrutinib discontinuation was 50%, while the ORR to ibrutinibbased therapy following idelalisib discontinuation was 77%. Responses to alternate BCRi were similar in patients who discontinued BCRi for toxicity and progression. However, the PFS seems shorter for those patients who changed the BCRi due to progressive disease. 9 The major reason for BCRi discontinuation is toxicity. Treatment with an alternate BCRi therapy is efficacious in >50% of patients. Non-overlapping toxicity profiles permit utilization of alternate BCRi following discontinuation due to toxicity. Mechanisms of BCRi resistance may not overlap and explain responses following discontinuation due to progression. 9 6

5 Congress Highlights CLL Pts still alive and not progressed (%) Addition of BR to Ibr did not impact the risk of progression or death Single-agent Ibr significantly reduced the risk of progression or death by 85% vs BR Months since baseline Ibr Ofa Ibr + BR BR Ibr (RESONATE, n=132) Ofa (RESONATE, n=132) Ibr + BR (HELIOS, n=287) BR (HELIOS, n=289) HR (95% CI) p Value ( ) < ( ) ( ) < Figure 2. Indirect comparison of PFS with ibrutinib monotherapy and ibrutinib in combination with bendamustine en rituximab. 8 Early activity of venetoclax monotherapy in patients with CLL relapsed after, or refractory to ibrutinib or idelalisib Venetoclax (ABT-199) is a selective, potent, oral BCL-2 inhibitor with a BCR and p53 independent mechanism of action and substantial activity in patients with heavily pretreated R/R CLL, including 17p deleted CLL. Preliminary results from an ongoing phase 2, open-label study evaluating venetoclax monotherapy in CLL patients R/R to ibrutinib or idelalisib has been reported. Patients with RT were ineligible. In total, 54 patients received venetoclax monotherapy starting at 20 mg followed by a 5-step weekly ramp-up to a final daily dose of 400 mg. The primary objectives were to assess the efficacy and safety of venetoclax. In the ibrutinib arm, 61% achieved a response at the week 8 assessment and 50% achieved a response in the idelalisb arm. No new Venetoclax monotherapy demonstrated early activity in patients R/R to BCRi. Responses seem similar in patients who have discontinued BCRi for refractory disease or intolerance. Venetoclax monotherapy exhibited a tolerable safety profile without events of clinical TLS using the weekly ramp-up protocol. 10 safety signals for venetoclax were observed. The most important AEs (all grades) were neutropenia (57%), anemia (35%), diarrhea (32%) and nausea (32%). One patient with high disease burden developed laboratory tumor lysis syndrome (TLS) in week 4. No patient experienced clinical TLS. 10 High overall response rate and acceptable toxicity with venetoclax in R/R CLL A pivotal phase 2, single-arm, multicenter study evaluated venetoclax monotherapy in patients with R/R CLL with a 17p deletion (N=107) (>7% cells by Vysis FISH probe in peripheral blood). Patients were treated daily with 400 mg venetoclax until disease progression or discontinuation for another reason after the weekly ramp-up dosing. The IRC-assessed ORR was 79.4% including deep responses (7.5% CR/CRi and 2.8% npr). 45 patients had an MRD assessment. Notably, 18 patients (17% of whole cohort, 21% of responders) had no detectable MRD in the PB. Ten of these patients were also tested in BM and 6 were found to be MRD-negative. Median time-to-first response was 0.8 months and the median time to CR/CRi was 8.2 months. Overall median DoR, PFS, and OS were not reached. The actuarial 12-month PFS and OS rates were 72.0% and 86.7%, respectively. In total, 37 patients discontinued treatment: 7

6 1 Special Edition 22 due to PD (9 RT), 9 due to AE, 2 withdrew consent, 1 was non-compliant; and 3 patients proceeded to an allo-sct (2 PR, 1 CR by IRC at time of transplant). Treatment-emergent AEs (all grades) were neutropenia (43%), diarrhea (29%), nausea (29%), anemia (27%), and fatigue (22%). Laboratory TLS was reported in 5 patients; none had clinical consequences. 11 Venetoclax monotherapy achieved a high ORR and sustained remissions with acceptable toxicity in R/R CLL patients with 17p deletion. More than 10% of all patients achieved deep responses (CR, CRi, or npr). Undetectable MRD was observed in >20% of responders. Such depth of response has not yet been reported for this population. 11 References 1. Janssens A, Van den Neste E, Offner F, Bron D. Updated BHS guidelines for the treatment of CLL, anno Belg J Hematol 2015, 6, Zelenetz A, Robak T, Coiffier B, et al. Idelalisib plus bendamustine nd rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: results of a phase 3 randomized double-blind placebo-controlled study. Blood 2015;126(23): Abstract LBA Burger J, Tedeschi A, Barr P, et al. Ibrutinib as initial therapy for patients with CLL. New Eng J Med, 2015, epub ahead of print. 4. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine and rituximab for previously treated CLL or SLL (HELIOS): a randomized, double-blind, phase 3 study. Lancet oncol, 2015, epub ahead of print. 5. Cramer P, Chanan-Khan A, Fraser G, et al. Improvement of quality of response with ibrutinib plus bendamustine/rituximab vs placebo plus bendamustine/rituximab for previously treated CLL/SLL. Blood 2015;126(23): Abstract Chanan-Khan A, Cramer P, Fraser G, et al. Impact of high-risk prognostic parameters and addition of ibrutinib to bendamustine/rituximab on outcomes for patients with relapsed CLL/SLL from the phase 3 double-blind HELIOS trial. Blood 2015;126(23): Abstract Chanan-Khan A, Cramer P, Fraser G, et al. Insights into the management of adverse events in patients with previously treated CLL/SLL: experience from the phase 3 Helios study of ibrutinib combined with bendamustine/rituximab. Blood 2015;126(23): Abstract Hillmen P, Fraser G, Jones J, et al. Comparing single-agent ibrutinib, bendamutine+rituximab (BR) and ibrutinib+br in patients with previously treated CLL/SLL. An indirect comparison of the Resonate and Helios trials. Blood 2015;126(23): Abstract Mato A, Barr P, Zent C, et al. Favorable outcomes in CLL patients with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study Blood 2015;126(23): Abstract Jones J, Mato A, Coutre S, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with CLL relapsed after or refractory to ibrutinib or idelalisib therapy. Blood 2015;126(23): Abstract Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the pivotal international phase 2 study. Blood 2015; 126(23): Abstract LBA-6. 8

Background. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy

Background. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract

More information

BENDAMUSTINE + RITUXIMAB IN CLL

BENDAMUSTINE + RITUXIMAB IN CLL BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,

More information

Chronic lymphocytic Leukemia

Chronic lymphocytic Leukemia Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive

More information

Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD

Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline

More information

BR is an established treatment regimen for CLL in the front-line and R/R settings

BR is an established treatment regimen for CLL in the front-line and R/R settings Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,

More information

MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients

MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November

More information

Management of 17p Deleted CLL Patients in the Era of Targeted Therapy

Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,

More information

Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division

Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic

More information

Idelalisib in the Treatment of Chronic Lymphocytic Leukemia

Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL

More information

CLL: future therapies. Dr. Nathalie Johnson

CLL: future therapies. Dr. Nathalie Johnson CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed

More information

Management of CLL in the Targeted Therapy Era

Management of CLL in the Targeted Therapy Era Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove

More information

CLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler

CLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer

More information

Advances in CLL 2016

Advances in CLL 2016 Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member

More information

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the

More information

Chronic lymphocytic leukemia

Chronic lymphocytic leukemia Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017 Disclosures Speaker

More information

CLL & SLL: Current Management & Treatment. Dr. Peter Anglin

CLL & SLL: Current Management & Treatment. Dr. Peter Anglin CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood

More information

Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)

Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following

More information

Chronic Lymphocytic Leukemia Update. Learning Objectives

Chronic Lymphocytic Leukemia Update. Learning Objectives Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend

More information

BTK Inhibitors and BCL2 Antagonists

BTK Inhibitors and BCL2 Antagonists BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer

More information

LEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA

LEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA

More information

We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT

We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

FCR and BR: When to use, how to use?

FCR and BR: When to use, how to use? FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal

More information

Clinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel

Clinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly

More information

CLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016

CLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016 CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2

More information

CLL treatment algorithm and state of the art

CLL treatment algorithm and state of the art CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups

More information

Update: Chronic Lymphocytic Leukemia

Update: Chronic Lymphocytic Leukemia ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8

More information

CLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic

CLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history

More information

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,

More information

CLL: Future Therapies. Dr. Anca Prica

CLL: Future Therapies. Dr. Anca Prica CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine

More information

CHRONIC LYMPHOCYTIC LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted

More information

NASDAQ: TGTX Jefferies Healthcare Conference June 2015

NASDAQ: TGTX Jefferies Healthcare Conference June 2015 NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,

More information

Update on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?

Update on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question? Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine

More information

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531

More information

Chronic lymphocytic leukemia

Chronic lymphocytic leukemia Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on

More information

CLL: disease specific biology and current treatment. Dr. Nathalie Johnson

CLL: disease specific biology and current treatment. Dr. Nathalie Johnson CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018

pan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 pan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is

More information

CHRONIC LYMPHOCYTIC LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This

More information

Chronic Lymphocytic Leukemia. Paolo Ghia

Chronic Lymphocytic Leukemia. Paolo Ghia Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela

More information

Outcomes of patients with CLL after discontinuing idelalisib

Outcomes of patients with CLL after discontinuing idelalisib Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts

More information

VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth

VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth ABT-199 Venetoclax ABT-199 is a selective, potent, orally

More information

LEUCEMIA LINFATICA CRONICA

LEUCEMIA LINFATICA CRONICA LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction

More information

Leukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington

Leukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody

More information

Management of Chronic Lymphatic Leukemia Beyond conventional therapy

Management of Chronic Lymphatic Leukemia Beyond conventional therapy 3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology

More information

Chronic Lymphocytic Leukemia: State of the Art

Chronic Lymphocytic Leukemia: State of the Art 14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics

More information

Mantle Cell Lymphoma. A schizophrenic disease

Mantle Cell Lymphoma. A schizophrenic disease 23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving

More information

2015 Oncology Annual Meeting in Chicago. prime Downloadable Slides in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.

2015 Oncology Annual Meeting in Chicago. prime Downloadable Slides in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. 2015 Oncology Annual Meeting in Chicago prime Downloadable Slides in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma May 29-June 2 Ibrutinib Combined With Bendamustine and Rituximab in Previously

More information

Advances in the treatment of Chronic Lymphocytic Leukemia

Advances in the treatment of Chronic Lymphocytic Leukemia Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute

More information

Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances

Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University

More information

Chronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015

Chronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers

More information

Dr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation

Dr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI

More information

Post-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford

Post-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford Post-ASH 2015 Chronic Lymphocytic Leukaemia Anna Schuh Consultant Haematologist Oxford NEWS IN FRONT-LINE Consort Diagram CLL10 Study: FCR VS BR in Front-line 688 CLL patients screened centrally for: immunophenotype

More information

Management of Patients With Relapsed Chronic Lymphocytic Leukemia

Management of Patients With Relapsed Chronic Lymphocytic Leukemia Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy

Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia

More information

Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities

Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Benjamin L. Lampson, Tiago R. Matos, Siddha N. Kasar, Haesook Kim, Elizabeth A. Morgan, Laura

More information

CME Information LEARNING OBJECTIVES

CME Information LEARNING OBJECTIVES CME Information LEARNING OBJECTIVES Apply recent clinical research findings with the newly FDA-approved combination of obinutuzumab and chlorambucil to the management and care of patients with previously

More information

pan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation

pan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation pan-canadian Oncology Drug Review Submitter or Manufacturer Feedback on a pcodr Expert Review Committee Initial Recommendation Venetoclax (Venclexta) Chronic Lymphocytic Leukemia March 2, 2018 3 Feedback

More information

CLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology

CLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Ibrutinib for treating chronic lymphocytic leukaemia.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Ibrutinib for treating chronic lymphocytic leukaemia. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Ibrutinib for treating chronic lymphocytic leukaemia Final scope Remit/appraisal objective To appraise the clinical and cost

More information

NASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference

NASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities

More information

UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD

UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD DISCLOSURE Speaker s bureau: Pharmacyclics, Janssen, Seattle Genetics, Astra Zeneca Consultant: Juno therapeutics, Astra Zeneca, BeiGene, Pharmacyclics

More information

allosct and CLL in the BCRi era time for a study

allosct and CLL in the BCRi era time for a study allosct and CLL in the BCRi era time for a study Patient characteristics in BCRi studies and allosct candidates DIFFER Facts on BCRi no Cure Risk factors for shorter BCRi efficacy in MV analysis? PA-refractory

More information

15 th Annual Miami Cancer Meeting

15 th Annual Miami Cancer Meeting 15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami

More information

Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy

Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Steven Coutre, MD Stanford Cancer Institute William G. Wierda, MD, PhD The University

More information

L approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro

L approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi

More information

Daratumumab: Mechanism of Action

Daratumumab: Mechanism of Action Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of

More information

CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia

CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

NASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017

NASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017 NASDAQ: TGTX J.P. Morgan Healthcare Conference January 2017 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

ASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)

ASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?) ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer

More information

The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS

The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview

More information

Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia

Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia Davy Chiodin with Nadia Ono Regulatory Science Acerta (A Member of the AstraZeneca Group) 09 November 2018 1

More information

POST ICML Indolent lymphomas relapse treatment

POST ICML Indolent lymphomas relapse treatment POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line

More information

Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria

Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment

More information

ANCO: ASCO Highlights 2018 Hematologic Malignancies

ANCO: ASCO Highlights 2018 Hematologic Malignancies ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships

More information

Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL

Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,

More information

Venetoclax in MCL. Prof. Le Gouill Nantes Medical University, France

Venetoclax in MCL. Prof. Le Gouill Nantes Medical University, France Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)

More information

Sequencing of chronic lymphocytic leukemia therapies

Sequencing of chronic lymphocytic leukemia therapies CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School

More information

BACKGROUND AND RATIONALE

BACKGROUND AND RATIONALE SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of

More information

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar

More information

New Targets and Treatments for Follicular Lymphoma

New Targets and Treatments for Follicular Lymphoma Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,

More information

Media Inquiries: Satu Glawe Phone: Bernadette King Phone:

Media Inquiries: Satu Glawe Phone: Bernadette King Phone: Media Inquiries: Satu Glawe Phone: +49-172-294-6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical

More information

CLL: State of the Art 2018

CLL: State of the Art 2018 CLL: State of the Art 2018 Dr. Susan O Brien, MD Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials

More information

Updates in Hematology

Updates in Hematology Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Bcl-2 inhibition in NHL. Jonathan W. Friedberg M.D., M.M.Sc.

Bcl-2 inhibition in NHL. Jonathan W. Friedberg M.D., M.M.Sc. Bcl-2 inhibition in NHL Jonathan W. Friedberg M.D., M.M.Sc. BCL-2, BH3 and apoptosis: Rational therapeutic targets in NHL Antiapoptotic proteins, prevent activation of Bax and Bak, thus inhibiting apoptosis.

More information

Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia

Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia This educational activity is supported by an educational grant from AbbVie Faculty Jennifer R Brown, MD PhD

More information

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint

More information

Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia

Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Mollie Moran, CNP The James Cancer Hospital at The Ohio State University Jeffrey Jones, MD/MPH Ohio State University Comprehensive

More information

CLINICAL TRIAL PROTOCOL

CLINICAL TRIAL PROTOCOL CLINICAL TRIAL PROTOCOL For reprint orders, please contact: reprints@futuremedicine.com The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/

More information

Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111)

Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia

More information

15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor

15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion

More information

B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care

B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care Dates of Certification: November 10, 2014-November 10, 2015 Medium: Print with online posttest, evaluation,

More information

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia December 1, 2016

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia December 1, 2016 pan-canadian Oncology Drug Review Initial Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia December 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report

More information

How to Integrate the New Drugs into the Management of Multiple Myeloma

How to Integrate the New Drugs into the Management of Multiple Myeloma How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients

More information

Medication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010

Medication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January

More information

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies

More information